Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
URGN 
UroGen Pharma Ltd (URGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: URGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $34.38
1 Year Target Price $34.38
| 5 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.1% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 621.99M USD | Price to earnings Ratio - | 1Y Target Price 34.38 |
Price to earnings Ratio - | 1Y Target Price 34.38 | ||
Volume (30-day avg) 8 | Beta 0.4 | 52 Weeks Range 3.42 - 18.15 | Updated Date 06/30/2025 |
52 Weeks Range 3.42 - 18.15 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -150.68% | Operating Margin (TTM) -182.26% |
Management Effectiveness
Return on Assets (TTM) -29.8% | Return on Equity (TTM) -1481.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 551048513 | Price to Sales(TTM) 6.77 |
Enterprise Value 551048513 | Price to Sales(TTM) 6.77 | ||
Enterprise Value to Revenue 6 | Enterprise Value to EBITDA -2.63 | Shares Outstanding 46107500 | Shares Floating 34390626 |
Shares Outstanding 46107500 | Shares Floating 34390626 | ||
Percent Insiders 6.87 | Percent Institutions 105.33 |
Analyst Ratings
Rating 3 | Target Price 34.38 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
UroGen Pharma Ltd
Company Overview
History and Background
UroGen Pharma Ltd. is a biopharmaceutical company founded in 2004. It focuses on developing and commercializing novel solutions for specialty cancers and urothelial diseases. Key milestones include the development and FDA approval of Jelmyto.
Core Business Areas
- Uro-Oncology: Focuses on developing and commercializing therapies for urothelial cancers, including non-muscle invasive bladder cancer (NMIBC).
- Specialty Urologic Diseases: Developing therapies for other urologic diseases beyond cancer.
Leadership and Structure
The leadership team includes Liz Barrett (President and CEO). The organizational structure includes departments for research and development, clinical trials, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Jelmyto (mitomycin gel): Jelmyto is a non-surgical treatment for low-grade upper tract urothelial cancer (LG-UTUC). Sales figures for Jelmyto vary but represent the primary revenue source for UroGen. Key competitors include traditional surgical procedures and other off-label chemotherapeutic approaches. Market share of Jelmyto in LG-UTUC is expanding, but definitive figures depend on regional and patient adoption rates.
Market Dynamics
Industry Overview
The uro-oncology market is growing due to an aging population and increasing prevalence of bladder and upper tract urothelial cancers. There is a significant unmet need for non-surgical treatment options.
Positioning
UroGen Pharma is positioned as a leader in non-surgical treatments for urothelial cancer. Its competitive advantage lies in its proprietary RTGel technology.
Total Addressable Market (TAM)
The TAM for LG-UTUC is estimated to be in the hundreds of millions of dollars annually. UroGen is positioned to capture a significant portion of this market with Jelmyto and future pipeline products.
Upturn SWOT Analysis
Strengths
- FDA-approved product (Jelmyto)
- Proprietary RTGel technology
- Focus on unmet needs in uro-oncology
- Experienced management team
Weaknesses
- Dependence on a single product (Jelmyto)
- Limited commercial infrastructure
- Requires reimbursement success
- Market penetration challenges
Opportunities
- Expansion of Jelmyto label to new indications
- Development of new products using RTGel technology
- Partnerships with larger pharmaceutical companies
- Geographic expansion into new markets
Threats
- Competition from established surgical procedures
- Emergence of new therapies for urothelial cancer
- Regulatory challenges
- Reimbursement hurdles
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- BMY
Competitive Landscape
UroGen has a novel drug delivery platform giving them an advantage, but faces strong competition from large pharmaceutical companies. Its limited resources are a disadvantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily tied to Jelmyto's launch and market penetration. Initial sales growth was substantial.
Future Projections: Future projections depend on Jelmyto's continued adoption, pipeline development, and partnership opportunities. Analyst estimates should be consulted.
Recent Initiatives: Recent strategic initiatives include expanding the commercial team, pursuing clinical trials for new indications, and exploring potential partnerships.
Summary
UroGen Pharma is a specialized biopharmaceutical company with a unique technology and approved drug. While promising, it is heavily reliant on Jelmyto sales and faces competition from larger, established players. Continued market penetration and pipeline development are crucial for its long-term success, particularly in the face of reimbursement uncertainty and potential market challenges. The company must strategically manage its resources and explore partnership opportunities to enhance its competitive position and broaden its portfolio.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is an estimate and may vary. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About UroGen Pharma Ltd
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2017-05-04 | President, CEO & Director Ms. Elizabeth A. Barrett | ||
Sector Healthcare | Industry Biotechnology | Full time employees 234 | Website https://www.urogen.com |
Full time employees 234 | Website https://www.urogen.com | ||
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.